BioCentury | Apr 8, 2013
Clinical News

Somatoprim: Phase IIa data

...company plans to start a Phase II trial this year. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | Jan 14, 2013
Clinical News

Somatoprim: Interim Phase Ib data

...Somatoprim is in a Phase IIa trial to treat acromegaly. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | Nov 19, 2012
Clinical News

Somatoprim: Phase IIa started

...300 µg octreotide in up to 20 untreated acromegaly patients. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | May 31, 2010
Finance

Performance Counts

...compounds and targets Oxxon Pharmaccines Ltd. Oxford BioMedica plc (LSE:OXB) $31.1 $33.0 Platform: vaccine technology Peptor Ltd....
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...opens in Germany. DeveloGen, a Global Life Science Ventures portfolio company , last year acquired Peptor Ltd....
...stem cell regeneration and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's...
BioCentury | May 17, 2004
Finance

Ebb & Flow

...Phase II trials to treat Type I diabetes. Coming off of its recent merger with Peptor...
...to partner two non-core preclinical products for cancer and myasthenia gravis and cancer inherited from Peptor...
BioCentury | May 17, 2004
Financial News

DeveloGen raises EUR 19 million

...Aventis (AVE). The company also announced shareholder approval of its previously announced stock merger with Peptor...
BioCentury | Nov 17, 2003
Strategy

Merger ups & downs

...the flip side last week, metabolic play DeveloGen AG (Goettingen, Germany) said it will acquire Peptor Ltd....
...Rehovot, Israel) in order to create an entity with the critical mass to go public. Peptor...
..."Peptor is an autoimmune play, but the most advanced products, which account for 90% of Peptor's...
BioCentury | Nov 17, 2003
Company News

DeveloGen, Peptor deal

...and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's clinical pipeline. Peptor's...
...and latent autoimmune diabetes in adults. DiaPep277 is partnered with Aventis S.A. (AVE, Strasbourg, France). Peptor...
...burn rate of about E12 million ($13.8 million) per year. DeveloGen AG , Goettingen, Germany Peptor Ltd....
BioCentury | Nov 13, 2003
Company News

DeveloGen, Peptor merging

...and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's clinical pipeline. Peptor's...
...Type I diabetes and latent autoimmune diabetes in adults. DiaPep277 is partnered with Aventis (AVE). Peptor...
Items per page:
1 - 10 of 33
BioCentury | Apr 8, 2013
Clinical News

Somatoprim: Phase IIa data

...company plans to start a Phase II trial this year. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | Jan 14, 2013
Clinical News

Somatoprim: Interim Phase Ib data

...Somatoprim is in a Phase IIa trial to treat acromegaly. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | Nov 19, 2012
Clinical News

Somatoprim: Phase IIa started

...300 µg octreotide in up to 20 untreated acromegaly patients. The compound was discovered at Peptor Ltd....
...Hamburg, Germany) in 2010 (see BioCentury, Sept. 13, 2010). The acquisition did not include the Peptor...
BioCentury | May 31, 2010
Finance

Performance Counts

...compounds and targets Oxxon Pharmaccines Ltd. Oxford BioMedica plc (LSE:OXB) $31.1 $33.0 Platform: vaccine technology Peptor Ltd....
BioCentury | Oct 4, 2004
Finance

Europe: The news will be light

...opens in Germany. DeveloGen, a Global Life Science Ventures portfolio company , last year acquired Peptor Ltd....
...stem cell regeneration and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's...
BioCentury | May 17, 2004
Finance

Ebb & Flow

...Phase II trials to treat Type I diabetes. Coming off of its recent merger with Peptor...
...to partner two non-core preclinical products for cancer and myasthenia gravis and cancer inherited from Peptor...
BioCentury | May 17, 2004
Financial News

DeveloGen raises EUR 19 million

...Aventis (AVE). The company also announced shareholder approval of its previously announced stock merger with Peptor...
BioCentury | Nov 17, 2003
Strategy

Merger ups & downs

...the flip side last week, metabolic play DeveloGen AG (Goettingen, Germany) said it will acquire Peptor Ltd....
...Rehovot, Israel) in order to create an entity with the critical mass to go public. Peptor...
..."Peptor is an autoimmune play, but the most advanced products, which account for 90% of Peptor's...
BioCentury | Nov 17, 2003
Company News

DeveloGen, Peptor deal

...and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's clinical pipeline. Peptor's...
...and latent autoimmune diabetes in adults. DiaPep277 is partnered with Aventis S.A. (AVE, Strasbourg, France). Peptor...
...burn rate of about E12 million ($13.8 million) per year. DeveloGen AG , Goettingen, Germany Peptor Ltd....
BioCentury | Nov 13, 2003
Company News

DeveloGen, Peptor merging

...and phenotype screens for targets in diabetes, obesity and metabolic syndrome, with Peptor's clinical pipeline. Peptor's...
...Type I diabetes and latent autoimmune diabetes in adults. DiaPep277 is partnered with Aventis (AVE). Peptor...
Items per page:
1 - 10 of 33